Financial News
Immunic gets a "positive surprise" from lead asset trial
April 13, 2023 at 08:00 AM EDT
Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).
Vitt describes it as "wonderful data" that came as a "positive surprise."
Contact Details
Proactive United States
Proactive United States
+1 347-449-0879
More News
View More
Broadcom Secures $460 Price Target, Implying +30% Upside
Today 12:12 EDT
Why Intuitive Surgical Is a No-Brainer for Long-Term Investors
Today 11:29 EDT
Analysts Think These Stocks Could More Than Double
Today 10:26 EDT
Can the SharkNinja Rally Continue? Analysts Think So
Today 10:14 EDT
Where 3M’s Q3 Report Says the Stock Price Is Heading
Today 9:05 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
